BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18951992)

  • 1. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial.
    Slobbe L; Boersma E; Rijnders BJ
    Pulm Pharmacol Ther; 2008 Dec; 21(6):855-9. PubMed ID: 18951992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
    Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
    Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
    Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis.
    Mihara T; Kakeya H; Izumikawa K; Obata Y; Nishino T; Takazono T; Kosai K; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Tsukamoto M; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
    J Infect Chemother; 2014 Feb; 20(2):104-8. PubMed ID: 24462443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
    Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
    Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
    Ho KM; Duff O; Chambers D; Murray R
    Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
    Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
    Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity.
    Fauvel M; Farrugia C; Tsapis N; Gueutin C; Cabaret O; Bories C; Bretagne S; Barratt G
    Int J Pharm; 2012 Oct; 436(1-2):106-10. PubMed ID: 22814222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: a meta-analysis.
    Xia D; Sun WK; Tan MM; Zhang M; Ding Y; Liu ZC; Su X; Shi Y
    Int J Infect Dis; 2015 Jan; 30():78-84. PubMed ID: 25461661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.
    Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
    J Pharm Pharmacol; 2005 Oct; 57(10):1289-95. PubMed ID: 16259757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.
    Penack O; Schwartz S; Martus P; Reinwald M; Schmidt-Hieber M; Thiel E; Blau IW
    Ann Oncol; 2006 Aug; 17(8):1306-12. PubMed ID: 16766594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
    Cornely OA; Leguay T; Maertens J; Vehreschild MJGT; Anagnostopoulos A; Castagnola C; Verga L; Rieger C; Kondakci M; Härter G; Duarte RF; Allione B; Cordonnier C; Heussel CP; Morrissey CO; Agrawal SG; Donnelly JP; Bresnik M; Hawkins MJ; Garner W; Gökbuget N;
    J Antimicrob Chemother; 2017 Aug; 72(8):2359-2367. PubMed ID: 28575414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.
    Kamalaporn H; Leung K; Nagel M; Kittanakom S; Calvieri B; Reithmeier RA; Coates AL
    Pediatr Pulmonol; 2014 Jun; 49(6):574-80. PubMed ID: 23843366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.